Aadi Drug Patent Portfolio
Aadi owns 1 orange book drug protected by 6 US patents Given below is the list of Aadi's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497737 | Pharmaceutical compositions of albumin and rapamycin | 28 Oct, 2040 | Active |
| US10973806 | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin | 29 Jun, 2036 | Active |
| US10705070 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | 05 Mar, 2036 | Active |
| US12061183 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | 05 Mar, 2036 | Active |
| US10206887 | Prion free nanoparticle compositions and methods of making thereof | 15 Apr, 2030 | Active |
| US8911786 | Nanoparticle comprising rapamycin and albumin as anticancer agent | 14 Feb, 2029 | Active |
Latest Legal Activities on Aadi's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Aadi.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 04 Mar, 2024 | US8911786 |
| transaction for FDA Determination of Regulatory Review Period | 28 Feb, 2024 | US8911786 |
| Second letter to regulating agency to determine regulatory review period | 05 Jan, 2024 | US8911786 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Dec, 2023 | US10705070 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US8911786 |
|
Recordation of Patent Grant Mailed
Critical
| 15 Nov, 2022 | US11497737 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 15 Nov, 2022 | US11497737 |
|
Email Notification
Critical
| 27 Oct, 2022 | US11497737 |
|
Issue Notification Mailed
Critical
| 26 Oct, 2022 | US11497737 |
|
Application Is Considered Ready for Issue
Critical
| 18 Oct, 2022 | US11497737 |
| Dispatch to FDC | 18 Oct, 2022 | US11497737 |
|
Issue Fee Payment Verified
Critical
| 12 Oct, 2022 | US11497737 |
|
Issue Fee Payment Received
Critical
| 12 Oct, 2022 | US11497737 |
|
Electronic Review
Critical
| 11 Oct, 2022 | US11497737 |
|
Mail Notice of Allowance
Critical
| 11 Oct, 2022 | US11497737 |
Aadi's Family Patents
Aadi drugs have patent protection in a total of 32 countries. It's US patent count contributes only to 22.2% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Aadi Drug List
Given below is the complete list of Aadi's drugs and the patents protecting them.
1. Fyarro
Fyarro is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497737 | Pharmaceutical compositions of albumin and rapamycin |
28 Oct, 2040
(15 years from now)
| Active |
| US10973806 | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin |
29 Jun, 2036
(11 years from now)
| Active |
| US10705070 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
05 Mar, 2036
(11 years from now)
| Active |
| US12061183 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
05 Mar, 2036
(11 years from now)
| Active |
| US10206887 | Prion free nanoparticle compositions and methods of making thereof |
15 Apr, 2030
(5 years from now)
| Active |
| US8911786 | Nanoparticle comprising rapamycin and albumin as anticancer agent |
14 Feb, 2029
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fyarro's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List